Main > A1. CORP. INDEX. B-Bm > BioGen./P C2 > 2010. 10.21.2010. CD20MAb/Genentech

---

Genentech will have responsibility for the further development of "ocrelizumab in multiple sclerosis (MS)". Genentech will fund 100% of the costs going forward and will be responsible for development and commercialization. Biogen Idec will receive tiered, double-digit royalties on US sales of ocrelizumab that will approximate its current "30% interest" in the compound.

In addition, Biogen Idec and Genentech have agreed that Biogen Idec will increase its share of the losses and profits related to the development and commercialization of "GA101" in the US to "35%" from 30%. GA101 is a next-generation anti-CD20 antibody in development for "CLL and NHL"

- George Scangos; Co.
- Dan Zabrowski; Roche

http://www.biogenidec.com/press_archive.aspx?ID=6015


2010. 10.21.2010. CD20MAb/Genentech's products
This section has no products